Dabigatran etexilate: Bleeding and prolonged dilute thrombin clotting time: 3 case reports.

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study involving 329 patients treated with idarucizumab for reversal of the effects of dabigatran etexilate between 1 April 2016 and 31 December 2018 at three hospitals in New Zealand, three patients [ I ages and sexes not stated i ] were described; they developed gastrointestinal bleeding (n=1), postoperative bleeding (n=1) and subdural haematoma with prolonged dilute thrombin clotting time (dTCT; n=1) during anticoagulant therapy with dabigatran etexilate. The patient, who developed gastrointestinal bleeding, resumed dabigatran etexilate, and the gastrointestinal bleeding recurred [ I not all outcomes stated i ]. [Extracted from the article]